Shots:The EC has approved Darzalex SC (daratumumab) for the treatment of adults with high‑risk smouldering multiple myeloma (SMM)Approval was based on the P-III (AQUILA) study data assessing Darzalex SC monotx. vs active monitoring in high-risk SMM pts (n=390)At a mFU of 65.2mos., trial showed improved PFS, with 63.1% vs 40.8% pts alive…
